- Home
- RC vs AVXL Comparison
RC vs AVXL Comparison
Compare RC & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- AVXL
- Stock Information
- Founded
- RC 2007
- AVXL 2004
- Country
- RC United States
- AVXL United States
- Employees
- RC N/A
- AVXL N/A
- Industry
- RC Real Estate Investment Trusts
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RC Real Estate
- AVXL Health Care
- Exchange
- RC Nasdaq
- AVXL Nasdaq
- Market Cap
- RC 907.7M
- AVXL 779.5M
- IPO Year
- RC N/A
- AVXL N/A
- Fundamental
- Price
- RC $5.03
- AVXL $8.63
- Analyst Decision
- RC Hold
- AVXL Strong Buy
- Analyst Count
- RC 8
- AVXL 2
- Target Price
- RC $7.58
- AVXL $44.00
- AVG Volume (30 Days)
- RC 4.2M
- AVXL 1.1M
- Earning Date
- RC 03-03-2025
- AVXL 05-08-2025
- Dividend Yield
- RC 18.61%
- AVXL N/A
- EPS Growth
- RC N/A
- AVXL N/A
- EPS
- RC N/A
- AVXL N/A
- Revenue
- RC N/A
- AVXL N/A
- Revenue This Year
- RC N/A
- AVXL N/A
- Revenue Next Year
- RC $7.26
- AVXL N/A
- P/E Ratio
- RC N/A
- AVXL N/A
- Revenue Growth
- RC N/A
- AVXL N/A
- 52 Week Low
- RC $4.74
- AVXL $3.25
- 52 Week High
- RC $9.54
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- RC 34.41
- AVXL 40.69
- Support Level
- RC $4.98
- AVXL $9.21
- Resistance Level
- RC $5.10
- AVXL $9.87
- Average True Range (ATR)
- RC 0.15
- AVXL 0.53
- MACD
- RC 0.05
- AVXL -0.06
- Stochastic Oscillator
- RC 29.49
- AVXL 6.63
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.